FTH: Short Sellers Retreat Ahead of Key Earnings and Index Addition

FTH heads into what may be its most consequential two-week stretch since going public, with short sellers pulling back sharply, analysts uniformly bullish, and an index inclusion announcement expected within days.

The most striking feature of the past month is how dramatically short positioning has unwound. Short interest in Faeth has fallen 37% over 30 days, dropping from above 2.3 million shares in late September to roughly 1.46 million. That still represents a structurally high 116% of the free float, an eyebrow-raising figure that reflects the thinness of the tradable share base rather than a traditional crowded-short setup. What matters more is the direction: shorts have been covering consistently, with a 21% reduction just in the past week. The borrow market has loosened in parallel. Availability has risen to 371%, meaning there are roughly 3.7 shares available to lend for every one already borrowed, a level that is comparatively relaxed given the history. The 52-week minimum availability was 0.5%, so the current reading is a world away from the squeeze conditions that have characterised this stock at its most charged. Cost to borrow has also eased, now running at 4.1% versus 7.9% at its October 2 peak, another sign that the pressure on shorts is structural rather than mechanical right now.

Street positioning could hardly be more one-sided. Every recent analyst action is a Buy or Outperform, with the mean price target at $55.31 against a current price of $19.65, implying the consensus sees roughly 180% upside from here. The most recent move came yesterday, when Guggenheim's Michael Schmidt trimmed his target by $1 to $69 while maintaining his Buy, a cosmetic reduction that changes nothing about the direction of travel. BTIG reiterated Buy at $55 last week, and William Blair initiated at Outperform in October. The bull case centres on PIKTOR's multi-node PI3K/mTOR blockade, an 80% ORR in early endometrial data, and differentiated tolerability, with management projecting peak sales of $794 million in endometrial cancer and $2.2 billion in breast cancer. Bears push back on breast cancer efficacy that fell below Street expectations at the Phase 1b/2 stage, widening competition from gedatolisib, and the near-certainty of further dilution if clinical momentum stalls. The company's earnings yield and EPS momentum scores rank in the bottom quartile of the market, as expected for a development-stage biotech burning cash, though the analyst recommendation divergence factor scores in the 97th percentile, capturing just how lopsided the Street view has become.

Ownership tells the story of a heavily institutionally-concentrated name. Khosla Ventures is the largest declared holder at 10.2% of shares, via VK Services. S2G Investments sits at just under 10%, Suvretta Capital at 7.8%, and Montanova Capital at 7.8%. Baker Bros., Balyasny, Cormorant and RA Capital all carry meaningful positions. Several of these are long-only specialist healthcare funds whose presence signals genuine conviction in the clinical thesis rather than opportunistic momentum trading. It is worth noting that two 13G/A amendments filed in August show ICS Opportunities and Caligan Partners each cutting their stakes from around 9 to 10% down to 3% or less, an exit of meaningful scale that absorbed significant supply. Those sellers are largely gone. The 13D/G register carries no activist holder, and positions are as-last-disclosed around the 5% threshold, with holders who fall below that level under no obligation to file again.

The index rebalance angle adds a near-term mechanical catalyst. ORTEX puts the probability of FTH joining both the Russell 2000 and Russell 3000 at the December 2026 Semi-Annual Review at 76%. The announcement is expected on November 13, one day after the company's next earnings print on November 12. The stock, at $508 million market cap, is 73% above the price that would trigger the inclusion rule, so the threshold is not in question. What matters is the flow: an estimated $48 million in forced buying from Russell 2000 trackers is pencilled in for the December 11 trade date. That is 6.6 days of the stock's normal daily volume. Historical data across 656 similar Russell additions shows a median move of minus 4% from announcement to effective date, with 55% moving in the expected direction and roughly 8.8 times normal volume on the trade day itself. The pattern is not uniform, but the mechanical buying pressure is real.

Earnings on November 12 are the immediate focus: the Phase 2 endometrial topline data the company has guided toward 4Q26 delivery may arrive alongside or shortly after that print, and both the index announcement and the clinical readout land within 24 hours of each other. That calendar compression is what to watch.